Composition: each tablet contains:

active substance: methotrexate – 2.5 mg or 5 mg.

Therapeutic indications

Lympho - and myeloblastic leukosis, neuroleukemia, myelomatosis, trophoblastomas (uterine chorioepithelioma, cystic mole, incl. invasive mole), esophageal cancer, epidermoid cancer of head and neck, cancer of urinary bladder, cancer of lung, liver cancer, breast cancer, renal carcinoma, cancer of ureters, prostate cancer, cervical cancer, cancer of vulva, ovarian cancer, testicular cancer, Hodgkin's and non-Hodgkin's lymphoma (incl. Burkitt's lymphoma), mycosis fungoides (local treatment), non-metastatic osteogenic sarcoma.

Rheumatoid arthritis (incl. Felty's syndrome), steroid-dependent bronchial asthma (if glucocorticoids are contraindicated), Crohn's disease, chronic nonspecific ulcerative colitis, lichen ruber planus, psoriasis, psoriatic arthritis, Reiter's syndrome, Sezary syndrome, disseminated sclerosis.


АТС code


Pharmaceutical form

film-coated tablets 2.5 mg and 5 mg

Storage conditions

Store in protected from moisture and light place at temperature below 25°C.